Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: A blood-free model in isolated mouse arteries

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 1, 2009, Pages

  Sennoun, Nacira ^a,b   Baron Menguy, Celine ^a   Burban, Mélanie ^c   Lecompte, Thomas ^d   Andriantsitohaina, Ramaroson ^a   Henrion, Daniel ^a   Mercat, Alain ^c,e   Asfar, Pierre ^c,e   Levy, Bruno ^b   Meziani, Ferhat ^a,e,f  

^a CNRS   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d INSERM   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Endothelial dysfunction; Endothelial nitric oxide synthase; Endotoxemia

Indexed keywords

ACETYLCHOLINE; DROTRECOGIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; POTASSIUM CHLORIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE B;

ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY DISEASE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTOXEMIA; EX VIVO STUDY; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPTIC SHOCK; SHEAR STRESS;

EID: 67650073169     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01133.2008     Document Type: Article

References (43)

1. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 187, Suppl 2: S364-S369, 2003.
2. Aird WC. Phenotypic heterogeneity of the endothelium. II. Representative vascular beds. Circ Res 100: 174-190, 2007.
3. Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 35: 69-75, 2007.
4. Bretschneider E, Uzonyi B, Weber AA, Fischer JW, Pape R, Lotzer K, Schror K. Human vascular smooth muscle cells express functionally active endothelial cell protein C receptor. Circ Res 100: 255-262, 2007.
5. Brueckmann M, Horn S, Lang S, Fukudome K, Schulze Nahrup A, Hoffmann U, Kaden JJ, Borggrefe M, Haase KK, Huhle G. Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb Haemost 93: 743-750, 2005.
6. Chauhan SD, Seggara G, Vo PA, Macallister RJ, Hobbs AJ, Ahluwalia A. Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. Faseb J 17: 773-775, 2003.
7. Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, MacAllister RJ. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 64: 172-178, 2004.
8. Connelly L, Madhani M, Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivo. J Biol Chem 280: 10040-10046, 2005.
9. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20: E83-E88, 2000.
10. Doursout MF, Oguchi T, Fischer UM, Liang Y, Chelly B, Hartley CJ, Chelly JE. Distribution of NOS isoforms in a porcine endotoxin shock model. Shock 29: 692-702, 2008.
11. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 75: 247-260, 2007.
12. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 13: 382-385, 2006.
13. Favory R, Lancel S, Marechal X, Tissier S, Neviere R. Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Med 32: 899-905, 2006.
14. Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth 93: 105-113, 2004.
15. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234, 1995.
16. Gupta A, Berg DT, Gerlitz B, Richardson MA, Galbreath E, Syed S, Sharma AC, Lowry SF, Grinnell BW. Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension. Shock 28: 468-476, 2007.
17. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11199-11203, 2001.
18. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med 32: S280-S286, 2004.
19. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 204: 2439-2448, 2007.
20. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 345: 588-595, 2001.
21. Looney MR, Matthay MA. Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury (Abstract). Crit Care 10: 239, 2006.
22. Lund DD, Brooks RM, Faraci FM, Heistad DD. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 293: H3726-H3731, 2007.
23. Malyshev E, Tazi KA, Moreau R, Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 22: 2195-2201, 2007.
24. Matsuda N, Hayashi Y, Takahashi Y, Hattori Y. Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy. J Pharmacol Exp Ther 319: 1348-1354, 2006.
25. Meziani F, Kremer H, Tesse A, Baron-Menguy C, Mathien C, Mostefai HA, Carusio N, Schneider F, Asfar P, Andriantsitohaina R. Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am J Pathol 171: 1753-1761, 2007.
26. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57: 217-252, 2005.
27. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 21: 361-374, 1991.
28. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31: 1573-1576, 2005.
29. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 109: 3161-3172, 2007.
30. Nacira S, Meziani F, Dessebe O, Cattan V, Collin S, Montemont C, Gibot S, Asfar P, Ramaroson A, Regnault V, Slama M, Lecompte T, Lacolley P, Levy B. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 37: 246-255, 2009.
31. O'Brien AJ, Wilson AJ, Sibbald R, Singer M, Clapp LH. Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. Br J Pharmacol 133: 351-360, 2001.
32. O'Brien LA, Gupta A, Grinnell BW. Activated protein C and sepsis. Front Biosci 11: 676-698, 2006.
33. Orfanos SE, Mavrommati I, Korovesi I, Roussos C. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med 30: 1702-1714, 2004.
34. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 60: 49-57, 2003.
35. Regnault V, Levy B. Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy? Crit Care 11: 103, 2007.
36. Russell JA. Management of sepsis. N Engl J Med 355: 1699-1713, 2006.
37. Stoclet JC, Martinez MC, Ohlmann P, Chasserot S, Schott C, Kleschyov AL, Schneider F, Andriantsitohaina R. Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock. Circulation 100: 107-112, 1999.
38. Stoclet JC, Muller B, Andriantsitohaina R, Kleschyov A. Overproduction of nitric oxide in pathophysiology of blood vessels. Biochemistry (Mosc) 63: 826-832, 1998.
39. Strunk V, Hahnenkamp K, Schneuing M, Fischer LG, Rich GF. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation. Anesth Analg 92: 681-687, 2001.
40. Wang Z, Su F, Rogiers P, Vincent JL. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 35: 2594-2600, 2007.
41. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110: 130-134, 2000.
42. Wiel E, Costecalde ME, Lebuffe G, Corseaux D, Jude B, Bordet R, Tavernier B, Vallet B. Activated protein C increases sensitivity to vasoconstriction in rabbit Escherichia coli endotoxin-induced shock. Crit Care 10: R47, 2006.
43. Yamaji K, Wang Y, Liu Y, Abeyama K, Hashiguchi T, Uchimura T, Krishna Biswas K, Iwamoto H, Maruyama I. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res 115: 319-325, 2005.